PEDIATRICS Vol. 94 No. 1 July 1994, pp. 132-133
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pope, J. F.
Right arrow Articles by Super, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pope, J. F.
Right arrow Articles by Super, D. M.

Concerned About Ribavirin Recommendations

John F. Pope MD1, James B. Besunder DO1, Mary L. Kumar MD1, and Dennis M. Super MD, MPH1

1 Dept of Pediatrics, Case Western Reserve University, School of Medicine, MetroHealth Medical Center, Cleveland, OH 44109-1998

The Committee on Infectious Diseases of the American Academy of Pediatrics recently published new guidelines for using ribavirin in treating respiratory syncytial virus (RSV).1 In updating previous guidelines, the Committee, based on the study by Smith et al,2 added the recommendation that all RSV-infected patients who require mechanical ventilation should receive ribavirin. We believe the Committee's broad recommendation for using this drug in mechanically ventilated patients is premature. We have concerns about the Smith study that call into question their conclusions regarding the efficacy of ribavirin in mechanically ventilated children.